Metformin
- Generic Name
- Metformin
- Brand Names
- Actoplus Met, Avandamet, Fortamet, Glucophage, Glucovance, Glumetza, Glycon, Invokamet, Janumet, Jentadueto, Kazano, Kombiglyze, Komboglyze, Qternmet, Riomet, Segluromet, Synjardy, Trijardy, Velmetia, Xigduo
- Drug Type
- Small Molecule
- Chemical Formula
- C4H11N5
- CAS Number
- 657-24-9
- Unique Ingredient Identifier
- 9100L32L2N
- Background
Metformin is a biguanide antihyperglycemic agent and first-line pharmacotherapy used in the management of type II diabetes.
Metformin is considered an antihyperglycemic drug because it lowers blood glucose concentrations in type II diabetes without causing hypoglycemia. It is commonly described as an "insulin sensitizer", leading to a decrease in insulin resistance and a clinically significant reduction of plasma fasting insulin levels. Another well-known benefit of this drug is modest weight loss, making it an effective choice for obese patients type II diabetes.
Metformin was first approved in Canada in 1972, and received subsequent FDA approval in the US in 1995.
- Indication
Metformin immediate-release formulations
Metformin is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients ≥10 years old with type 2 diabetes mellitus.
Metformin extended-release tablet (XR)
The extended-release formulation of metformin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Safety in children has not been determined to this date.
Metformin combination products
Metformin is a component of a variety of combination products with other anti-diabetic agents. It is indicated, along with diet and exercise, to improve glycemic control in adult patients with type 2 diabetes mellitus in combination with DPP-4 inhibitors (sitagliptin, linagliptin, alogliptin, or saxagliptin), in combination with SGLT2 inhibitors (canagliflozin, empagliflozin, ertugliflozin, or dapagliflozin), or in combination with pioglitazone.
- Associated Conditions
- Cardiovascular Mortality, End Stage Renal Disease (ESRD), Hospitalizations, Polycystic Ovarian Syndrome (PCOS), Type 2 Diabetes Mellitus, Decreased estimated glomerular filtration rate
- Associated Therapies
- -
A Study to Evaluate the Effect of ASP1941 in Adult Patients With Type 2 Diabetes Mellitus
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2010-02-19
- Last Posted Date
- 2024-11-06
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 412
- Registration Number
- NCT01071850
- Locations
- 🇺🇸
CSRA Partners in Health, Inc., Augusta, Georgia, United States
🇺🇸Atlanta Vascular Research Foundation, Atlanta Cardiology & Primary Care P.C., Tucker, Georgia, United States
🇮🇳Bride, Bharti Hospital, Karnal, India
Endometrial Effects of Metformin Action in Women With Polycystic Ovarian Syndrome (PCOS)
- Conditions
- Polycystic Ovarian Syndrome
- Interventions
- First Posted Date
- 2010-02-17
- Last Posted Date
- 2020-03-30
- Lead Sponsor
- Yale University
- Target Recruit Count
- 14
- Registration Number
- NCT01070160
- Locations
- 🇺🇸
Yale-New Haven Hospital Women's Center, New Haven, Connecticut, United States
Bioequivalence Study of Fixed Dose Combination of 2.5 mg Saxagliptin/850 mg Metformin Tablet Relative to 2.5 mg Onglyza and 850 mg Glucophage Tablets Co-Administered
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2010-02-15
- Last Posted Date
- 2015-05-08
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 24
- Registration Number
- NCT01068743
- Locations
- 🇺🇸
PPD Development, LP, Austin, Texas, United States
Effect of Different Insulin Administrations, All in Combination With Metformin, on Glycaemic Control in Subjects With Type 2 Diabetes Inadequately Controlled by Oral Anti-diabetic Drugs
- Conditions
- DiabetesDiabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2010-02-15
- Last Posted Date
- 2017-01-13
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 403
- Registration Number
- NCT01068652
- Locations
- 🇹🇳
Novo Nordisk Investigational Site, Tunisia, Tunisia
A Study in Participants With Type 2 Diabetes Mellitus
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2010-02-08
- Last Posted Date
- 2015-01-26
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 978
- Registration Number
- NCT01064687
- Locations
- 🇵🇷
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Yabucoa, Puerto Rico
Study Of Safety And Efficacy Of Ertugliflozin (PF-04971729, MK-8835) In Participants With Type 2 Diabetes (MK-8835-016)
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Drug: Placebo to ErtugliflozinDrug: Ertugliflozin 5 mgDrug: Placebo to SitagliptinDrug: Ertugliflozin 1 mgDrug: Ertugliflozin 25 mgDrug: Sitagliptin 100 mgDrug: Metformin
- First Posted Date
- 2010-02-01
- Last Posted Date
- 2018-09-13
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 375
- Registration Number
- NCT01059825
A Study Comparing the Amount of Metformin and After Taking a Combination Tablet vs. Separate Tablets
- Conditions
- Healthy Volunteers
- Interventions
- First Posted Date
- 2010-01-26
- Last Posted Date
- 2012-06-01
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 120
- Registration Number
- NCT01055691
- Locations
- 🇩🇪
Research Site, Berlin, Germany
A Study to Compare Taspoglutide and Insulin Glargine in Insulin-Naïve Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin and Sulfonylurea Combination Therapy
- Conditions
- Diabetes Mellitus Type 2
- Interventions
- First Posted Date
- 2010-01-18
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 370
- Registration Number
- NCT01051011
Safety Study of BMS-770767 in Subjects With Type 2 Diabetes
- First Posted Date
- 2010-01-12
- Last Posted Date
- 2015-10-12
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 76
- Registration Number
- NCT01046422
- Locations
- 🇺🇸
Nevada Alliance Against Diabetes, Las Vegas, Nevada, United States
🇺🇸Marina Raikhel, Md, Lomita, California, United States
🇰🇷Local Institution, Suwon, Korea, Republic of
Myo-inositol Versus Metformin Administration in Post-menopausal Women With Metabolic Syndrome
- First Posted Date
- 2010-01-12
- Last Posted Date
- 2014-05-20
- Lead Sponsor
- University of Messina
- Target Recruit Count
- 100
- Registration Number
- NCT01046500
- Locations
- 🇮🇹
University Hospital, Messina, Italy
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.